Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,719 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Disorders Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms

NCT00160472
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
removal of ovarian vessels
Procedure
Lead sponsor
United States Department of Defense
Federal
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 26, 2010 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 1 Interventional

A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment

NCT00933972
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
RO4998452
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 17, 2026, 2:49 PM EDT
Recruiting No phase listed Observational

Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)

NCT06837181
View directory record Official record
Conditions
Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes, Diabetes, Retinopathy, Neuropathy, Nephropathy, Blood Pressure, Cardiovascular Risk, Microvascular
Interventions
observational study
Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 1 Interventional

Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

NCT00426712
View directory record Official record
Conditions
Hepatitis B
Interventions
1018 ISS immunostimulatory oligonucleotide with HBV surface antigen, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
40 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Costa Mesa, California • Brooklyn Center, Minnesota • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 17, 2026, 2:49 PM EDT
Terminated No phase listed Observational

Genetic Susceptibility to Kidney Cancer

NCT00854022
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Early Phase 1 Interventional

Carbamylation in Renal Disease-modulation With Amino Acid Therapy

NCT01612429
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis
Interventions
Amino acid supplementation
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2016 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 1 Interventional

Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer

NCT02318771
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Metastatic Renal Cell Cancer, Recurrent Head and Neck Carcinoma, Recurrent Lung Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Skin Carcinoma, Stage III Renal Cell Cancer, Stage IV Lung Cancer, Stage IV Skin Melanoma
Interventions
Radiation Therapy (RT), MK-3475
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 1 Interventional

Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets

NCT00195936
View directory record Official record
Conditions
Hypophosphatemic Rickets, X-Linked Dominant
Interventions
Cinacalcet
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
5 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis

NCT02504294
View directory record Official record
Conditions
Chronic Kidney Disease (CKD)
Interventions
Epoetin Hospira Arm, Standard of Care Arm, IV Iron
Biological · Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
42
States / cities
Chula Vista, California • Poway, California • Rancho Bernardo, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Not applicable Interventional

A One Visit Follow Up of Adults With Fabry Disease Who Started Long-term Enzyme Replacement Therapy As Children

NCT04002531
View directory record Official record
Conditions
Quality of Life, Renal Insufficiency, Cardiac Event
Interventions
General and Neurological examination, Vital signs, 12 lead electrocardiogram, Echocardiogram, Blood draw, Urine collection, 2-hour Holter Monitor, Brief Pain Inventory questionnaire, Quality of Life questionnaire
Other · Procedure
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 1 Interventional

A Study of a Renal Autologous Cell Therapy (REACT) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT).

NCT04115345
View directory record Official record
Conditions
Chronic Kidney Disease, Congenital Anomalies of Kidney and Urinary Tract
Interventions
Renal Autologous Cell Therapy (REACT)
Biological
Lead sponsor
Prokidney
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Meridian, Idaho • Neptune City, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

NCT01672775
View directory record Official record
Conditions
Carcinoma, Renal Cell, Renal Cell Carcinoma of Papillary Histology, Renal Cell Carcinoma With Clear Cell Histology, Renal Cell Carcinoma With Non-Clear Cell Histology
Interventions
AGS-16C3F
Drug
Lead sponsor
Agensys, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
5
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 17, 2026, 2:49 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage

NCT05853601
View directory record Official record
Conditions
Acute Kidney Injury, HIE
Interventions
Single Dose Theophylline, Repeat Dose Theophylline
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Hour to 18 Hours
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 17, 2026, 2:49 PM EDT
Withdrawn Not applicable Interventional

Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients

NCT01033500
View directory record Official record
Conditions
Islets of Langerhans Transplantation, Diabetes Mellitus, Type 1, Kidney Transplantation
Interventions
Belatacept
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 8, 2013 · Synced Oct 17, 2026, 2:49 PM EDT
Completed No phase listed Observational

Evaluation of Albuminuria HIV-Infected Patients

NCT00524992
View directory record Official record
Conditions
HIV-Associated Focal Segmental Glomerulosclerosis, HIV-Associated Collapsing Glomerulopathy, Proteinuria, Albuminuria, Renal Tubular Toxicity
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 17, 2026, 2:49 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Assessment of Sodium Sulfide in Subjects With Impaired Renal Function

NCT00879645
View directory record Official record
Conditions
Renal Impairment
Interventions
Sodium Sulfide
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 17, 2026, 2:49 PM EDT
Withdrawn No phase listed Observational

Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy

NCT01146353
View directory record Official record
Conditions
Influenza, Renal Failure
Interventions
Not listed
Lead sponsor
Midwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 1 Interventional

IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

NCT03758781
View directory record Official record
Conditions
Metastatic Cancer, Recurrent Cancer, Solid Tumor, Renal Cell Carcinoma, Urothelial Carcinoma, NSCLC, Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
IRX 2, Nivolumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 4 Interventional Results available

Study of Tomography of Nephrolithiasis Evaluation

NCT01451931
View directory record Official record
Conditions
Urolithiasis
Interventions
Point-of-care Ultrasound, Radiology Ultrasound, Radiology CT
Other · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
2,776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Fresno, California • Sacramento, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 17, 2026, 2:49 PM EDT
Terminated Phase 1 Interventional

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

NCT03549000
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS), Ovarian Cancer, Renal Cell Carcinoma (RCC), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
NZV930, PDR001, NIR178
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Not applicable Interventional Results available

A Translational Approach to Gitelman Syndrome

NCT00822107
View directory record Official record
Conditions
Gitelman Syndrome
Interventions
Hydrochlorothiazide
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 17, 2026, 2:49 PM EDT
Not listed Not applicable Interventional

Comparison of Conventional Dialysis and the Allient System

NCT00788905
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Failure
Interventions
Allient System
Device
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 2 Interventional Results available

Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT00413777
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
11
States / cities
Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 2:49 PM EDT
Recruiting Phase 1 Interventional

A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma

NCT07688187
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
PD-32766D (a Copper-64 [64Cu] labeled peptide), PD-32766T (an Actinium-225 [225Ac] labeled peptide)
Drug
Lead sponsor
PeptiDream Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 17, 2026, 2:49 PM EDT